Parkinson disease Systemic and orofacial manifestations, medical and dental management

被引:49
作者
Friedlander, Arthur H. [1 ,2 ,3 ]
Mahler, Michael [4 ,5 ]
Norman, Keith M.
Ettinger, Ronald L. [6 ,7 ]
机构
[1] VA Greater Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA 90073 USA
[2] Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA
[3] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA
[4] VA Greater Angeles Healthcare Syst, Neurobehav Clin, Los Angeles, CA 90073 USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[6] Univ Iowa, Dept Prosthodont, Iowa City, IA USA
[7] Univ Iowa, Dows Inst Dent Res, Iowa City, IA USA
关键词
Parkinson disease; local anesthetics; saliva; BOTULINUM-TOXIN-A; ORAL-HEALTH; NONMOTOR SYMPTOMS; FOLLOW-UP; DIAGNOSIS; DYSFUNCTION; DOPAMINE; DEMENTIA; LEVODOPA; THERAPY;
D O I
10.14219/jada.archive.2009.0251
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background. More than 1.5 million Americans have Parkinson disease (PD), and this figure is expected to rise as the population ages. However, the dental literature offers little information about the illness. Types of Studies Reviewed. The authors conducted a MEDLINE search using the key terms "Parkinson's disease, "medical management" and "dentistry." They selected contemporaneous articles published in peer-reviewed journals and gave preference to articles reporting randomized controlled trials. Results. PD is a progressive neurodegenerative disorder caused by loss of dopaminergic and nondopaminergic neurons in the brain. These deficits result in tremor, slowness of movement, rigidity, postural instability and autonomic and behavioral dysfunction. Treatment consists of administering medications that replace dopamine, stimulate dopamine receptors and modulate other neurotransmitter systems. Clinical Implications. Oral health may decline because of tremors, muscle rigidity and cognitive deficits. The dentist should consult with the patient's physician to establish the patient's competence to provide informed consent and to determine the presence of comorbid illnesses. Scheduling short morning appointments that begin 90 minutes after administration of PD medication enhances the patient's ability to cooperate with care. Inclination of the dental chair at 45 degrees, placement of a bite prop, use of a rubber dam and high-volume oral evacuation enhance airway protection. To avoid adverse drug interactions with levodopa and entacapone, the dentist should limit administration of local anesthetic agents to three cartridges of 2 percent lidocaine with 1:100,000 epinephrine per half hour, and patients receiving selegiline should not be given agents containing epinephrine or levonordefrin. The dentist should instruct the patient and the caregiver in good oral hygiene techniques.
引用
收藏
页码:658 / 669
页数:12
相关论文
共 101 条
  • [1] Beating a dead horse - Dopamine and Parkinson disease
    Ahlskog, J. Eric
    [J]. NEUROLOGY, 2007, 69 (17) : 1701 - 1711
  • [2] Alexander Roger E., 2000, General Dentistry, V48, P572
  • [3] Experience with microelectrode guided subthalamic nucleus deep brain stimulation
    Amirnovin, R
    Williams, ZM
    Cosgrove, GR
    Eskandar, EN
    [J]. NEUROSURGERY, 2006, 58 (02) : 96 - 102
  • [4] [Anonymous], 2003, COCHRANE DATABASE SY
  • [5] Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease
    Asanuma, Masato
    Miyazaki, Ikuko
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (14) : 1428 - 1434
  • [6] Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo
    Bar-Am, O
    Yogev-Falach, M
    Amit, T
    Sagi, Y
    Youdim, MBH
    [J]. JOURNAL OF NEUROCHEMISTRY, 2004, 89 (05) : 1119 - 1125
  • [7] BEGHERI H, 1999, CLIN NEUROPHARMACOL
  • [8] WEIGHT CHANGE AND BODY-COMPOSITION IN PATIENTS WITH PARKINSONS-DISEASE
    BEYER, PL
    PALARINO, MY
    MICHALEK, D
    BUSENBARK, K
    KOLLER, WC
    [J]. JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 1995, 95 (09) : 979 - 983
  • [9] Bhat V, 2005, Minerva Med, V96, P145
  • [10] Ophthalmologic features of Parkinson's disease
    Biousse, V
    Skibell, BC
    Watts, RL
    Loupe, DN
    Drews-Botsch, C
    Newman, NJ
    [J]. NEUROLOGY, 2004, 62 (02) : 177 - 180